A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

Inclusion Criteria:

• Have chronic AD that has been present for ≥1 year before the screening period orhave chronic eczema and meet the AAD criteria.

• Have moderate-to-severe AD, including all of the following at the baseline: EASIscore ≥16, IGA score ≥3 (scale of 0 to 4), ≥10% BSA of AD involvement.

• Have a documented history provided by a physician and/or investigator of inadequateresponse to existing topical medications within 6 months preceding screening asdefined by at least 1 of the following:

1. Inability to achieve good disease control, defined as mild disease or betterafter use of at least a medium-potency TCS for at least 4 weeks, or for themaximum duration recommended by the product prescribing information, whicheveris shorter. TCS may be used with or without TCIs and/or topical Janus kinase (JAK) inhibitors.

2. Participants who failed systemic therapies intended to treat AD within 6 monthspreceding screening, such as cyclosporine, MTX, azathioprine, and MMF, willalso be considered as surrogates for having inadequate response to topicaltherapy.

• Adolescents body weight must be ≥40 kg at baseline.

• Males may participate in this trial and comply with specific local government studyrequirements. Females of childbearing potential and females not of childbearingpotential may participate in this trial.

Exclusion Criteria:

• Have received a dose of lebrikizumab in any prior lebrikizumab clinical study.

• Have a history of anaphylaxis or uncontrolled chronic disease that might requirebursts of oral corticosteroids.

• Have a current or recent acute, active infection. For at least 30 days beforescreening and up to the randomization, participants must have no symptoms or signsof confirmed or suspected infection and must have completed any appropriateanti-infective treatment.

• Have had Serious, Opportunistic, Chronic and Recurring infection within 3 monthsprior to the screening or develops any of these infections before the randomization.

• Have active tuberculosis (TB) or latent tuberculosis infection (LTBI) that has notbeen treated with a complete course of appropriate therapy or such treatment isunderway.

• Have a current infection with HBV, HCV, human immunodeficiency virus (HIV)infection.

• Have presence of skin comorbidities that may interfere with study assessments.

• Have a diagnosis or history of malignant disease within 5 years before screening,with the following exceptions:

1. basal cell or squamous epithelial carcinomas of the skin that have beenresected with no evidence of metastatic disease for 3 years, and

2. cervical carcinoma in situ, with no evidence of recurrence within 5 yearsbefore screening visit.

• Pregnant or breastfeeding women or women planning to become pregnant or breastfeedduring the study.